Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

KPTI

Phase 3

XPOVIO (Selinexor) (XPO1 inhibitor) + ruxolitinib

Myelofibrosis

H2 2025

SENTRY/ XPORT-MF-034 trial: 6/28/23- Initiated pivotal Ph3 trial. Long-term data & Ph1 biomarker data at ASH '23. 11/1/23- Updated Ph1 data in 2024. Ph3 trial design at ASCO '24. Top-line data in H2 2025.

Data readout

VKTX

Phase 2

VK2735 (Oral formulation)

Metabolic and endocrine disorders, obesity

H2 2025

VENTURE Trial. 3/26/24- Positive Ph1 MAD results. 7/24/24- Initiate Ph2 study in Q4 2024. 11/4/24 Present Ph1 data at Obesity Week '24 including data from 80 mg & 100 mg cohorts. 1/8/25- Initiated Ph2 VENTURE trial. 2/5/25- Data in H2 2025.

Data readout

CTMX

Phase 1

CX-801 + KEYTRUDA

Metastatic melanoma

H2 2025

In collab w/ MRK. 1/24/24- IND cleared. 1/6/25- Dose escalation ongoing. 3/6/25- Initial translational and biomarker data in H2 2025.

Data readout

NRIX

Phase 1a/b

NX-2127

B-cell malignacies, CLL (Chronic Lymphocytic Leukemia), NHL (Non-Hodgkin's Lymphoma)

2025

11/1/23- Partial clinical hold. 3/11/24- Partial clinical hold lifted, enrollment reinitiated. 1/13/25- Complete dose escalation w/ new controlled drug. Additional data after selection of Ph1b dose in 2025.

Data readout

ADAG

Phase 1b/2

Muzastotug (ADG126) + KEYTRUDA® (pembrolizumab)

3L Microsatellite stable colorectal cancer (MSS CRC)

2025

1/27/25- Presented updated data at ASCO GI. 3/24/25- Provide long-term-time-to-event data in 2025.

Data readout

SDGR

Phase 1

SGR-3515

Acute myeloid leukemia or myelodysplastic syndrome

H2 2025

5/1/24- FDA cleared IND application. 7/31/24- Initiates Ph 1 dose-escalation trial. 10/23/24- New preclinical data presentation at ENA 2024. 2/26/25- Initial data in H2 2025.

Data readout

NTLA

Phase 1

nexiguran ziclumeran (nex-z) (NTLA-2001)

ATTR (Transthyretin Amyloidosis) + ATTR-CM

2025

MAGNITUDE trials. 3/18/24- First patient dosed. 6/25/24- Ph1 POC data at PNS annual meeting. 11/16/24- Reported new data. 1/9/25- Dose first patient in Q1 2025 (MAGNITUDE-2). Present longer-term data in 2025.

Data readout

TIL

Phase 1b/2

AXN-2510/IMM2510 + chemotherapy

Non-Small Cell Lung Cancer (NSCLC)

H2 2025

1/14/25- First patient dosed in China. 3/4/25- Initial clinical data in H2 2025.

Data readout

IONS

Phase 3

IONIS-APOCIII-LRx (Olezarsen)

sHTG (severe hypertriglyceridemia)

H2 2025

6/25/24- Enrollment completed in CORE, CORE2 and ESSENCE trials with results in H2 2025.

Data readout

SANA

Phase 1

SC262

Relapsed or refractory (r/r) B-cell malignancies

2025

VIVID trial. 11/4/24- Continues enrollment in Ph1 with data in 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20